ERBB2 and neoplasm: The PBPK-PD model properly describes the time course of MBQ-167 in plasma and other tissues (e.g., lungs, heart, liver, kidneys, spleen) and predicts tumor growth inhibition when administered to mice in two BC cell lines, HER2+ and Triple Negative.